Compound 19” is a JAK1/TYK2 dual kinase inhibitor from Pfizer, related to its clinical JAK1/TYK2 dual inhibitor, brepocitinib, in Ph. II for a variety of inflammatory diseases. The cyclopropyl amide group was designed to displace a high energy water molecule. It was probably fortunate for their manufacturing colleagues that brepocitinib was
< 1 minute read
Sep. 17, 2021
Compound 19: a JAK1/TYK2 dual kinase inhibitor
“Compound 19”
JAK1/TYK2-selective dual kinase inhibitor oral activity in arthritis model from SBDD of prior internal matter Bioorg. Med. Chem. Lett., Mar. 31, 2020 Pfizer, Cambridge, MA and Groton, CT
Loading...
